^
Association details:
Biomarker:No biomarker
Cancer:Adrenal Cortex Carcinoma
Drug:Lysodren (mitotane) (Steroid receptor inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A1 - Approval
Title:

Mitotane (Lysodren) is not recommended for use within NHS Scotland

Published date:
11/10/2006
Excerpt:
CONTRADICTING EVIDENCE: Mitotane (Lysodren) is not recommended for use within NHS Scotland for the symptomatic treatment of advanced (unresectable, metastatic or relapsed) adrenal cortical carcinoma.
Evidence Level:
Sensitive: A1 - Approval
Published date:
04/28/2004
Excerpt:
Symptomatic treatment of advanced (unresectable, metastatic or relapsed) adrenal cortical carcinoma. The effect of Lysodren on non-functional adrenal cortical carcinoma is not established.
Evidence Level:
Sensitive: A1 - Approval
New
Source:
Excerpt:
LYSODREN is an adrenal cytotoxic agent indicated for the treatment of inoperable, functional or nonfunctional, adrenal cortical carcinoma.
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
Adrenocortical Carcinoma: other recommended regimen... Mitotane
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
In most patients with metastatic ACC, first-line therapy with mitotane alone or mitotane plus ChT is recommended; EDP-M is the first-line treatment of choice…